AstraZeneca PLC Ordinary Shares (AZN) Covered Calls

AstraZeneca PLC Ordinary Shares covered calls AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its primary therapeutic areas include oncology, rare diseases, and biopharmaceuticals, covering cardiovascular, renal, metabolism, respiratory, and immunology. The company operates a vast international manufacturing and research network, delivering innovative treatments for complex diseases to patients in over one hundred countries.

You can sell covered calls on AstraZeneca PLC Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AZN (prices last updated Fri 3:15 PM ET):

AstraZeneca PLC Ordinary Shares (AZN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
204.75 +0.24 204.66 204.85 1.8M - 269
Covered Calls For AstraZeneca PLC Ordinary Shares (AZN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 200 5.50 199.35 0.3% 13.7%
Mar 20 200 8.05 196.80 1.6% 16.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

AstraZeneca operates as a premier innovation-driven healthcare provider. The company specializes in converting complex laboratory breakthroughs into transformative medicines. Its diverse portfolio is built around high-growth segments that provide essential treatments for chronic and life-threatening conditions. Their primary offerings include:

  1. Oncology: Leading-edge cancer therapies such as Tagrisso, Imfinzi, and Lynparza, alongside next-generation antibody-drug conjugates.
  2. Cardiovascular, Renal, and Metabolism: Essential medicines like Farxiga that address interconnected chronic conditions.
  3. Respiratory and Immunology: Advanced biologics and inhaled therapies, including Fasenra and Breztri, for asthma and autoimmune disorders.
  4. Rare Disease: Specialized treatments for ultra-rare conditions through its Alexion division, focusing on complement system biology.

Competitive Landscape

The biopharmaceutical industry is characterized by intense competition for market share and intellectual property. AstraZeneca competes with other global giants such as Novartis and GSK across several therapeutic categories. In the oncology and immunology spaces, it encounters significant competition from Merck & Co. and Pfizer. Additionally, as the company expands its cardiometabolic and weight management pipeline, it faces rivals like Novo Nordisk and Eli Lilly. For rare disease treatments, the company is often challenged by innovators like Amgen and various biotechnology firms specializing in gene-editing and cell therapy.

Strategic Outlook and Innovation

AstraZeneca is executing a long-term growth strategy centered on doubling its annual revenue by the end of the decade through the launch of dozens of new medicines. A major strategic priority is the onshoring of manufacturing to ensure that medicines sold in North America are produced within the region to mitigate global supply chain risks. Innovation efforts are increasingly focused on AI-discovered drugs and automated R&D workflows, which aim to significantly compress drug discovery timelines and improve clinical success rates. The company is also investing heavily in "AI Factories" for healthcare, using multimodal foundation models to redefine precision medicine in oncology. By leveraging these advanced technologies and expanding its presence in high-density life science hubs, the bank aims to lead the industry in sustainable biopharmaceutical production and patient-centric care.